Rapid and Visual Detection of 2019 Novel Coronavirus (Sars-Cov-2) by a Reverse Transcription Loop-Mediated Isothermal Amplification Assay
C. Yan,J. Cui,L. Huang,B. Du,L. Chen,G. Xue,S. Li,W. Zhang,L. Zhao,Y. Sun,H. Yao,N. Li,H. Zhao,Y. Feng,S. Liu,Q. Zhang,D. Liu,J. Yuan
DOI: https://doi.org/10.1016/j.cmi.2020.04.001
IF: 13.31
2020-01-01
Clinical Microbiology and Infection
Abstract:Objective: To evaluate a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and compare it with RTPCR. Methods: We designed primers specific to the orf1ab and S genes of SARS-CoV-2. Total viral RNA was extracted using the QIAamp Viral RNA Mini Kit. We optimized the RT-LAMP assay, and evaluated it for its sensitivity and specificity of detection using real-time turbidity monitoring and visual observation. Results: The primer sets orf1ab-4 and S-123 amplified the genes in the shortest times, the mean (+/- SD) times were 18 +/- 1.32 min and 20 +/- 1.80 min, respectively, and 63 degrees C was the optimum reaction temperature. The sensitivities were 2 x 10(1) copies and 2 x 10(2) copies per reaction with primer sets orf1ab-4 and S-123, respectively. This assay showed no cross-reactivity with 60 other respiratory pathogens. To describe the availability of this method in clinical diagnosis, we collected 130 specimens from patients with clinically suspected SARS-CoV-2 infection. Among them, 58 were confirmed to be positive and 72 were negative by RT-LAMP. The sensitivity was 100% (95% CI 92.3%-100%), specificity 100% (95% CI 93.7% e100%). This assay detected SARS-CoV-2 in a mean (+/- SD) time of 26.28 +/- 4.48 min and the results can be identified with visual observation. Conclusion: These results demonstrate that we developed a rapid, simple, specific and sensitive RT-LAMP assay for SARS-CoV-2 detection among clinical samples. It will be a powerful tool for SARS-CoV-2 identification, and for monitoring suspected patients, close contacts and high-risk groups. (C) 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.